iZafe Group secures SEK 5.5 million loan and cancels previously issued warrants of series TO14B Page 1

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER PROVISIONS. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

STOCKHOLM, SE / ACCESSWIRE / August 21, 2024 / iZafe Group (STO:IZAFE-B) iZafe Group AB (“iZafe Group” or the “Company”), a company engaged in the research, development and marketing of digital medical solutions and services for safer medication management at home, today announces that the Board of Directors of iZafe Group has decided to enter into a SEK 5.5 million loan agreement (the “Loan”) issued by Exelity AB (the “Lender”). The Loan has been secured as the Board has determined that the issuance of warrants series TO14B (the “Warrants”) would entail excessive administrative costs and financial uncertainty.